Verification evidence is still being completed.
PDF / print export
CasZyme
Vilnius, Lithuania
- Verified lead
- Dr. Giedrius Gasiūnas
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Chief Executive Officer and Co-Founder
- 2026 technical specialization
- CRISPR-Cas Technology
- Review cycle
- May 2026
- Full address
- Mokslininku st. 2, Vilnius, Lithuania
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Caszyme leadership page confirming the current chief executive record.
- Editorial note
- CRISPR and genome-editing platform with enzyme-discovery depth, diagnostics relevance, and defensible intellectual-property value.
CRISPR-Cas Technology
ISO 9001:2015
CRISPR and genome-editing platform with enzyme-discovery depth, diagnostics relevance, and defensible intellectual-property value.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
CRISPR and genome-editing platform with enzyme-discovery depth, diagnostics relevance, and defensible intellectual-property value.
- Lead
- Dr. Giedrius Gasiūnas (verified ↗)
- Address
- Mokslininku st. 2, Vilnius, Lithuania (source ↗)
- Compliance
- ISO 9001:2015
- Last reviewed
- 14 Mar 2026 (3mo ago)
- Scale
- Molecular
- Capabilities
- CRISPR Platform Development · Nuclease Characterization · Gene Editing Tools
- Founded
- 2017
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Dr. Giedrius Gasiūnas
Chief Executive Officer and Co-Founder
Full addressMokslininku st. 2, Vilnius, Lithuania
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Caszyme contact page listing Mokslininku st. 2, Vilnius, Lithuania.
Open sourceMolecular
Vilnius, Lithuania. CRISPR-Cas Technology. Review completed on 14 Mar 2026.
National Health Authority
ISO 9001:2015
CRISPR-Cas Technology
CRISPR and genome-editing platform with enzyme-discovery depth, diagnostics relevance, and defensible intellectual-property value.
Editorial note
The current public record follows Caszyme's live leadership page and Vilnius contact surface rather than the earlier interim-transition wording.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
CRISPR Platform Development
Nuclease Characterization
Gene Editing Tools
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
NGS Sequencers
PCR Systems
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
14 Mar 2026: Executive identity confirmed via official management disclosure.
14 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is CasZyme located?
- CasZyme operates from Mokslininku st. 2, Vilnius, Lithuania, Vilnius, Lithuania.
- Who runs CasZyme?
- CasZyme is led by Dr. Giedrius Gasiūnas, Chief Executive Officer and Co-Founder. Verified 14 Mar 2026.
- What certifications does CasZyme hold?
- CasZyme is documented under ISO 9001:2015.
- What does CasZyme do?
- CRISPR and genome-editing platform with enzyme-discovery depth, diagnostics relevance, and defensible intellectual-property value. Core capabilities: CRISPR Platform Development, Nuclease Characterization, Gene Editing Tools.
Editorial context
Related technical briefs
Briefs that name Vilnius as a covered market or city.